Nkarta Inc (NAS:NKTX)
$ 2.87 -0.12 (-4.01%) Market Cap: 202.53 Mil Enterprise Value: 4.93 Mil PE Ratio: 0 PB Ratio: 0.47 GF Score: 38/100

Nkarta Inc to Discuss NKX101 and NKX019 Clinical Data Call Transcript

Apr 25, 2022 / 12:00PM GMT
Release Date Price: $18.72 (+140.93%)
Operator

Thank you for standing by. Welcome to the Nkarta conference call to review preliminary clinical data for NKX101 and NKX019. (Operator Instructions) Please be advised that this call is being recorded at the company's request.

I would now like to turn the call over to the company.

Greg Mann
Nkarta, Inc. - VP of Public Affairs and IR

Thank you, operator, and good morning, everyone. I'm Greg Mann, Senior Vice President, Public Affairs and Investor Relations at Nkarta. Thank you for joining our call this morning.

Earlier today, Nkarta issued a press release announcing clinical data on 2 programs, NKX101 and NKX019. This press release, today's webcast and corresponding slides are available on our website. We're looking forward to discussing these 2 sets of preliminary results as we advance toward making engineered CAR-NK cell therapy a reality for cancer patients. On the call today from Nkarta are Paul Hastings, President and Chief Executive Officer; Dr. Kanya Rajangam, Chief Medical Officer; and Dr. Nadir Mahmood, Chief Financial and Business

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot